english.prescrire.org > Spotlight > Archives : 2020 > Aflibercept (Eylea°) in diabetic macular oedema without visual impairment

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2020 : 1 | 30 | 60

In the July-August issue of Prescrire International: aflibercept (Eylea°) in diabetic macular oedema without visual impairment

FREE DOWNLOAD What is the efficacy of aflibercept in patients with diabetic macular oedema without visual impairment at the time of diagnosis?
Full text available for free download.

In practice

  • For diabetic patients who have macular oedema with no loss of visual acuity, treatment from the outset with intravitreal injections of a aflibercept does not seem to offer any tangible advantage compared to observation in preventing deterioration of visual acuity.
  • There is no justification for early exposure of patients to the sometimes serious adverse effects of this anti‐VEGF.
  • It is better to reserve its use for patients with marked or worsening visual impairment.

©Prescrire 1 July 2020

Source: "Diabetic macular oedema without visual impairment. No benefit from immediate treatment with aflibercept" Prescrire International 2020; 29 (217): 190. Free.

Enjoy full access to Prescrire International, and support independent information

Share on  Facebook Share on  Twitter

See also:

"Aflibercept (Eylea°) and
diabetic macular oedema"
(September 2015)

Read more:

All the subjects in
Prescrire's Spotlight
Free >